Ascension Ventures is a leading UK-based seed investor focused on early-stage technology startups with a particular emphasis on impact businesses that address significant global challenges. The firm manages a range of tax-efficient and institutional funds, providing capital and support to entrepreneurs aiming to make a positive societal impact. Since its inception in 2015, Ascension has invested in over 150 startups and has over £100 million under management, with a track record of twelve exits and recognition as a top seed VC by UKBAA in 2022.

Ascension Ventures

The Ascension Syndicate

Ascension is an early-stage venture capital firm built and managed by exited operators and entrepreneurs to back the next generation of tech and impact founders. 

Since 2015, Ascension has invested in 150+ start-ups across its (S)EIS & Institutional Funds – our specialist approach and extensive sector reach allow us to identify and scale pioneering tech enterprises. 

With over £83m under management and twelve exits, Ascension is the most active VC in London over the past decade (Beauhurst) and is UKBAA's Seed VC of the Year in 2022.
 
Ascension is particularly focused on backing impact businesses leveraging the power of technology to solve some of the world’s biggest problems.

Guardian Angel

Entale Media

Credit Kudos

ZigZag Global

Libryo

Looop Online Limited

Albert

Alva

ChilliConnect

Chosen AI

Cliff.ai

Wayra

Ascension

Why We Invested in Heatio: An Energy Market Disruptor! 

Read this article to discover how their mission to democratise access to low-carbon technologies and their innovative use of IoT for optimal energy savings are set to revolutionise the energy market. 🚀

First exit alert!!

We are delighted to announce our first exit from the Ascension Life Fund! Aparito, a company that provides digital technology solutions to improve clinical trials for rare diseases, has recently been acquired by Eli Lilly and Company.

Aparito's Atom5™ platform enables clinical trials to be conducted in patients' homes using disease-specific smartphone apps, video assessments, and wearable technology to collect electronic clinical outcome assessments (eCOAs) and digital biomarkers. This acquisition allows Lilly to incorporate Aparito's technology into its clinical trials, enhancing data collection and improving the experience for patients participating in studies, especially those with rare diseases.

The acquisition, in May 2024, comes less than 6 months after the Fund’s investment and represents a significant uplift in valuation.

Congratulations to Elin Haf Davies and the whole Aparito team, it was a pleasure working with you!

We need your help! 🚗 🙏 

We're experiencing a surge in demand for The Electric Car Scheme and need talented individuals to join us! If you know someone interested, please share the link below with them or reach out to me directly here on LinkedIn.

We ensure everyone has what they need to succeed, fostering a supportive team environment. This includes rewards, opportunities for development, and being a valued part of our journey together.

You can learn more about working with us here: https://lnkd.in/eqXWTar8

(No external recruiters please)

#TheElectricCarScheme #SalarySacrifice

📣 Ascension's Latest Newsletter, a few highlights include: 

➡ We are UKBAA finalists for Seed VC of the Year and Emma Steele for Best Woman-Led Investment in Innovation 
➡ Ascension Fund III deal number 3, Heatio
➡ Interview with Charlotte Bax, Founder of Captur
➡ Saltroad.com - Speech & Language Therapy, Ascension S/EIS Fund 23-24 investment 
➡ Juniver is looking for clinical trial participants

🔗 Excited about what we're doing at Ascension? Stay in the loop by subscribing to our newsletter here - https://zcmp.eu/u5FE

#founders #venturecapital #investment

What a way to start the week, announcing Juniver, Ascension Fund III’s deal number 2! 🌟

🚀Juniver's vision is to transform the $66bn eating disorder market through an innovative, first-of-its-kind digital solution. With its AI-powered assistant providing on-demand help through urges, personalised insights from health data, peer support, and telemedicine care, it aims to reduce eating disorder symptoms, lower relapse rates, and maintain healthy eating habits for all. 🚀

🔍 Why Juniver stands out
Superstar founder: Emilie Faure has impressed us from day one with her visionary approach and unwavering dedication to addressing the challenges of eating disorders through technology.
Broad & smart routes to market: including primary care practitioners, university distribution, paediatrics, and step-down therapy/triage for residential treatment centres.
Unique value propositions: by providing a low-cost app with a personalised AI-powered assistant, Juniver can offer accessible and effective care, particularly for lower-income individuals who are disproportionately affected by the costs associated with eating disorders.

📚 Juniver's Impact Theory of Change
Juniver’s research indicates that economic hardship can exacerbate eating disorders.
Barriers to accessing care, including costs, stigma, and the complexity of navigating health systems delay treatment, impacting outcomes. 
Juniver’s affordable, accessible, and empowering solution helps people get help early, in a way that fits with their lives.

Juniver’s commitment to improving access to care and supporting long-term health and wellbeing, particularly for lower-income consumers, aligns perfectly with our investment thesis. We are excited to be on this journey and support Juniver in its US expansion.

#VentureCapital #Innovation #HealthTech #EatingDisorders #Juniver

⭐ FINAL APPLICATION DEADLINE APPROACHING! ⭐

Are you looking for a world class co-founder? Pre-seed funding? Time to develop your idea? The right introductions? All of the above?

We are curating a world-class group of innovators and entrepreneurs - and this is your opportunity to join them!

Our next venture building cohort, dedicated to building businesses that tackle a critical challenge facing the health people or the planet, kicks off in June - and applications will close on Wednesday 15th May.

We invest in👇

🌍 Domain experts in climate & health 🌍 
Entrepreneurial people with deep insight into an important problem in health or the environment, and ideas for the solution they plan to build to solve it.

📈 Business & technical leaders 📈 
People who are ready to apply their commercial, product, engineering or technical expertise to build and scale a mission-led startup in health or environment.

🥼 Entrepreneurial scientists 🥼
People who have already developed innovative deep tech or science with the potential for high impact in health or the environment, and are now ready to think about commercialisation.

Why build your venture at Zinc?

✅ Capital - up to £300k as the first investor in your business
✅ Team building - access to world-class co-founders and hires
✅ Expertise - access to hundreds of curated expert fellows and advisors
✅ Community - office space and a network of hundreds of like-minded innovators
✅ Venture Building Platform - venture building resources and hands-on support
✅ Coaching - personal and team development
✅ Partnerships - access to innovation partnerships and grant funding
✅ Fundraising - strategy, support and introductions
✅ Technical support - R&D, scientific and IP advisory
✅ Cash - a six month stipend while you experiment and build

Are you ready to take the next step and join world-class innovators building their businesses at Zinc?

👇 Don't delay, submit your application ahead of the deadline at midnight on 15th May - https://www.zinc.vc/

Ella Goldner (Levy) | Paul Kirby | Eleanor Ford | Shelley Brown | Luke Charbonnier-Bevan, PhD | Rosie Webster | Caitlin Scheybeler | Kate Hyslop | Hannah Abdel-Hadi

msh id	VC:ASCENSION
symbol	-
name	Ascension Ventures
homepage url	https://ascension.vc
country	GB
sector	Financial Services & Finance
industry	Venture Capital & Private Equity
market	PRIVATE
employee count	49
crunchbase url	https://www.crunchbase.com/organization/ascension-ventures-limited
linkedin url	https://www.linkedin.com/company/ascensionvc
founders	-

market cap	-
enterprise value	-
stage	-
raised capital	-
valuation	-

monthly webtraffic	-
monthly webtraffic growth	-
growth score 14	-
growth score 28	-
growth score 90	-
growth score 365	-

revenue ltm	-
gross profit ltm	-
ebitda ltm	-
net income ltm	-
revenue ntm	-
gross profit ntm	-
ebitda ntm	-
net income ntm	-

growth cost and expenses	-
growth cost of revenue	-
growth depreciation and amortization	-
growth ebitda	-
growth ebitda ratio	-
growth eps	-
growth eps diluted	-
growth general and administrative expenses	-
growth gross profit	-
growth gross profit ratio	-

VC:ASCENSION

Ascension Ventures

Company Information

Market Metrics

Web & Growth Metrics

LTM & NTM Metrics

Growth & Performance Metrics

Operating Metrics

Balance Sheet Metrics

Financial Metrics (2022-2026)

cost and expenses	-
cost of revenue	-
depreciation and amortization	-
ebitda	-
ebitda ratio	-
eps	-
eps diluted	-
operating expenses	-
operating income	-
operating income ratio	-

accounts receivables	-
capital expenditure	-
cash at beginning of period	-
cash at end of period	-
inventory	-
working capital ttm	-

	2022	2023	2024	2025	2026
Revenue Metrics
Revenue	-	-	-	-	-
Revenue Growth	-	-	-	-	-
Revenue Multiple	-	-	-	-	-
Profit Metrics
Gross Profit	-	-	-	-	-
Gross Profit Growth	-	-	-	-	-
Gross Profit Multiple	-	-	-	-	-
EBITDA Metrics
EBITDA	-	-	-	-	-
EBITDA Growth	-	-	-	-	-
EBITDA Multiple	-	-	-	-	-
Net Income Metrics
Net Income	-	-	-	-	-
Net Income Growth	-	-	-	-	-
Net Income Multiple	-	-	-	-	-